Most of these data in cancer cells were confirmed in an independent study by Demma et al., who showed that recombinant and chemically synthesized Omomyc penetrated cells through an ATP-dependent mechanism, localized in their nuclei (in particular in the nucleoli) and showed in vitro efficacy in lymphoma and colon cancer cells with deregulated Myc. This evidence concerns the gene MYC and lymphoma.